Literature DB >> 22406913

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.

Teri S Krebs1, Pål-Ørjan Johansen.   

Abstract

Assessments of lysergic acid diethylamide (LSD) in the treatment of alcoholism have not been based on quantitative meta-analysis. Hence, we performed a meta-analysis of randomized controlled trials in order to evaluate the clinical efficacy of LSD in the treatment of alcoholism. Two reviewers independently extracted the data, pooling the effects using odds ratios (ORs) by a generic inverse variance, random effects model. We identified six eligible trials, including 536 participants. There was evidence for a beneficial effect of LSD on alcohol misuse (OR, 1.96; 95% CI, 1.36-2.84; p = 0.0003). Between-trial heterogeneity for the treatment effects was negligible (I² = 0%). Secondary outcomes, risk of bias and limitations are discussed. A single dose of LSD, in the context of various alcoholism treatment programs, is associated with a decrease in alcohol misuse.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22406913     DOI: 10.1177/0269881112439253

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  94 in total

Review 1.  Psychedelic medicine: a re-emerging therapeutic paradigm.

Authors:  Kenneth W Tupper; Evan Wood; Richard Yensen; Matthew W Johnson
Journal:  CMAJ       Date:  2015-09-08       Impact factor: 8.262

Review 2.  REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

3.  Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.

Authors:  Farhana Sakloth; Elizabeth Leggett; Megan J Moerke; E Andrew Townsend; Matthew L Banks; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2019-01-10       Impact factor: 3.157

Review 4.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

5.  Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin.

Authors:  Alexander V Lebedev; Martin Lövdén; Gidon Rosenthal; Amanda Feilding; David J Nutt; Robin L Carhart-Harris
Journal:  Hum Brain Mapp       Date:  2015-05-22       Impact factor: 5.038

6.  Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Authors:  Albert Garcia-Romeu; Roland R Griffiths; Matthew W Johnson
Journal:  Curr Drug Abuse Rev       Date:  2014

Review 7.  The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Authors:  Robin L Carhart-Harris; Guy M Goodwin
Journal:  Neuropsychopharmacology       Date:  2017-04-26       Impact factor: 7.853

8.  Mind-altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?: Science & Society series on "Drugs and Science".

Authors:  David Nutt
Journal:  EMBO Rep       Date:  2014-02-14       Impact factor: 8.807

9.  LSD-induced entropic brain activity predicts subsequent personality change.

Authors:  A V Lebedev; M Kaelen; M Lövdén; J Nilsson; A Feilding; D J Nutt; R L Carhart-Harris
Journal:  Hum Brain Mapp       Date:  2016-05-06       Impact factor: 5.038

10.  Long-term follow-up of psilocybin-facilitated smoking cessation.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Roland R Griffiths
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-21       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.